Olverembatinib (HQP1351) (BCR-ABL1 Inhibitor)

May 12, 2026 — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) announced that 17 clinical advances across its core hematology assets will be presented at the 31st European Hematology Association Congress (EHA2026) in Stockholm (June 11–14, 2026), including 8 poster presentations. Featured programs include olverembatinib (HQP1351; China’s first approved third-generation BCR-ABL inhibitor) and lisaftoclax (APG-2575; the first approved China-developed selective BCL-2 inhibitor).

Highlighted poster abstracts cover: updated efficacy/safety of olverembatinib as second-line therapy in chronic-phase CML (PS1733); olverembatinib activity in CP-CML patients resistant to ponatinib or asciminib with ASXL1 mutations (PS1727); updated POLARIS-1 Part 1 data (global registrational Phase 3) combining olverembatinib with low-intensity chemotherapy in newly diagnosed Ph+ ALL (PS1479); prognostic baseline factors from a pivotal Phase 2 lisaftoclax study in CLL/SLL (PS1713); and Phase 1b safety/preliminary efficacy of olverembatinib+lisaftoclax in pediatric R/R Ph+ ALL (PS1473). The company notes neither drug is FDA-approved in the US, underscoring ongoing global registrational development and international visibility of its hematology pipeline.